Compass Therapeutics Inc.
NASDAQ:CMPX
Compass Therapeutics Inc.
Total Current Liabilities
Compass Therapeutics Inc.
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
Total Current Liabilities
$12.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$39.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
10%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Total Current Liabilities
$23.5m
|
CAGR 3-Years
54%
|
CAGR 5-Years
27%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
Compass Therapeutics Inc.
Glance View
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).
See Also
What is Compass Therapeutics Inc.'s Total Current Liabilities?
Total Current Liabilities
12.4m
USD
Based on the financial report for Sep 30, 2025, Compass Therapeutics Inc.'s Total Current Liabilities amounts to 12.4m USD.
What is Compass Therapeutics Inc.'s Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
5%
Over the last year, the Total Current Liabilities growth was 180%. The average annual Total Current Liabilities growth rates for Compass Therapeutics Inc. have been 9% over the past three years , 5% over the past five years .
